TG4 Stock Overview
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.0001 |
52 Week High | €0.0073 |
52 Week Low | €0.0001 |
Beta | 0.51 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
TG4 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 4.5% | 1.4% |
1Y | n/a | 34.0% | 7.5% |
Return vs Industry: Insufficient data to determine how TG4 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how TG4 performed against the German Market.
Price Volatility
TG4 volatility | |
---|---|
TG4 Average Weekly Movement | 27.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TG4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TG4's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 20 | Pascal Ghoson | https://www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME.
Oxurion NV Fundamentals Summary
TG4 fundamental statistics | |
---|---|
Market cap | €575.40k |
Earnings (TTM) | -€27.82m |
Revenue (TTM) | €515.00k |
1.1x
P/S Ratio0.0x
P/E RatioIs TG4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TG4 income statement (TTM) | |
---|---|
Revenue | €515.00k |
Cost of Revenue | €437.00k |
Gross Profit | €78.00k |
Other Expenses | €27.90m |
Earnings | -€27.82m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0048 |
Gross Margin | 15.15% |
Net Profit Margin | -5,402.72% |
Debt/Equity Ratio | -114.6% |
How did TG4 perform over the long term?
See historical performance and comparison